Billions of diagnostic tests are performed each year to detect antibodies as indicators of disease....
Enable Biosciences's award-winning ultra-sensitive technology couples specific DNA tags with antigens that are used to detect the presence of highly specific antibodies in your blood, saliva, or other bodily fluids.
he National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a one-year Phase I Small Business Innovative Research (SBIR) grant for $225,000 in funding to Enable Biosciences to develop an improved Lyme disease test.
Hamilton Company and Enable Biosciences are pleased to announce their collaboration to provide fully automated processing of up to 96 liquid biopsy samples at one time using a novel ultra-sensitive and highly specific immunoassay in a hands-free workflow.
The Microlab STAR optimized for the ADAP assay technology will be co-promoted by Hamilton and Enable Biosciences, and a single, localized point of contact will enable researchers to seamlessly integrate the automated workflow into their laboratory, while leveraging the respective expertise and services of each Company.
Welcome to Enable Biosciences’ Scientist Spotlight, a semi-regular blog post highlighting one of our scientists working to bring Enable’s technology to fruition.
Tell us a little bit about yourself.
Hi all, I’m Jordan! I’m a Bay Area native who recently graduated from the University of California, Davis with a B.S. in Genetics and Genomics and a B.A. in Linguistics (go Ags!). At Davis, in addition to school, I also enjoyed being a member on the Division 1 NCAA Women’s Swim Team.
Chief Scientific Officer Dr. Peter Robinson gave an invited talk to our friends at Quartzy!
San Francisco, CA, October 22, 2018 – Enable Biosciences Inc. has moved to a new location in South San Francisco to accommodate growth and to launch a new clinical testing facility.
Since 2016, Enable Biosciences has been housed at MBC Biolabs, a biotechnology incubator located in the Dogpatch neighborhood in San Francisco. Now a team of six scientists, engineers, and physicians, Enable plans to expand to include clinical scientists in anticipation of the launch of their blood and saliva tests for type 1 diabetes, lyme disease, and food allergy over the next year. The new facility spans 3,488 square feet over two floors, with refurbished lab facilities and office space.
Enable Biosciences has been selected from over 300 NIH Phase 2 grant awardees to participate in the 2018 - 2019 National Institutes of Health Commercial Accelerator Program (CAP). Per the NIH: “The CAP is well-regarded for its combination of deep domain expertise and access to industry connections which have resulted in measurable gains and accomplishments by participating companies.” The NIH further describes: “The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.”
SAN FRANCISCO, Sept. 20, 2018 /PRNewswire/ -- Enable Biosciences Inc. has been awarded a National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) Small Business Innovation Research (SBIR) Phase I grant for $223,806 to accelerate development of its minimally invasive, ultrasensitive, and specific blood tests for food allergy.
"Food allergies affect up to 9% of the US population, with over 30,000 reactions per year requiring emergency care. For many, especially children, allergic reactions are serious and life-threatening," said David Seftel, MD, MBA, Enable's CEO. "Mitigating and preventing adverse allergic events require accurate diagnosis to direct dietary avoidance, connect patients with novel treatments and to monitor response to treatment."